InFlectis BioScience is leveraging its leading expertise in the cellular defense system against misfolded proteins and drug discovery to identify and develop small molecules which modulate key proteins involved in misfolded protein disorders.

Endoplasmic Reticulum (ER) proteostasis is vital for cellular function and cell survival. Many different perturbations can alter the folding capacity of the ER and may cause accumulation of unfolded or misfolded proteins inside the ER, a cellular condition referred to as ER stress.  To safeguard proteostasis, the mammalian ER has a complex machinery to maintain the integrity of cells. This adaptive programme is called the unfolded protein response (UPR).

Through its expertise in modulating protein-protein interaction, InFlectis BioScience develops novel therapies that can potentially ameliorate the large number of pathological conditions arising from the accumulation of defective proteins, including the common neurodegenerative diseases.

IFB-088 is InFlectis BioScience’s lead candidate that modulate the UPR through a new and validated protein-protein interaction (phosphatase PP1/PPP1R15A). IFB-088 is a first-in-class drug candidate with the potential to be used to treat orphan neurodegenerative diseases, such as Charcot-Marie-Tooth and Retinal diseases in the first instance.

InFlectis BioScience also intend to develop additional compound family’s drug candidates to go through several approvals for non-orphan indications to treat other age-related diseases involving misfolded proteins.